___

• Bernot A, Clepet C, Dasilva C, on behalf of the French FMF consortium. A candidate gene for familial mediterranean fever. Nat Genet 1997; 17(1): 25-31.
• Ben-Chetrit E, Touitou I. Familial Mediterranean Fever in the World. Arthritis Rheum 2009; 61(10): 1447– 53.
• Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84(1): 1–11.
• Cobankara V, Fidan G, Turk T, Zencir M, Colakoglu M, Ozen S. The prevalence of familial Mediterranean fever in the Turkish province of Denizli: a field study with a zero patient design. Clin Exp Rheumatol 2004; 22(4 suppl 34): 527–30.
• Onen F, Sumer H, Turkay S, Akyurek O, Tunca M, Ozdogan H. Increased frequency of familial Mediterranean fever in Central Anatolia, Turkey. Clin Exp Rheumatol. 2004; 22(4 Suppl 34): 31-4.
• Kisacik B, Yildirim B, Tasliyurt T, et al. Increased frequency of familial Mediterranean fever in northern Turkey: a population-based study. Rheumatol Int. 2009; 29(11): 1307-17.
• Etem E, Deveci SD, Erol D, Yuce H, Elyas H. Familial Mediterranean Fever: A Retrospective Clinical and Molecular Study in the East of Anatolia Region of Turkey. Open Rheumatol J 2010; 4: 1-6.
• Yilmaz E, Ozen S, Balci B, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 2001; 9(7): 553-5.
• Tüzün A, Dursun A, Ateş Y, et al. Ailesel Akdeniz Ateşi düşünülen 110 vakada sık görülen MEFV gen mutasyonları analiz sonuçları ve klinik bulgularla korelasyonu. Gülhane Tıp Dergisi 2004; 46 (3): 238-41.
• Coker I, Colak A, Yolcu I, et al. MEFV gene mutation spectrum in familial Mediterranean fever (FMF): a single center study in the Aegean region of Turkey. Z Rheumatol 2011; 70(6): 511-6.
• Örün E, Yalcınkaya F, Özkaya N, Akar N, Gökçe H. Ailevi Akdeniz Ateşi (AAA) Hastalığında akut faz yanıtı ile tümör nekrozis faktör-α, interlökin-8 ve interlökin-6 düzeylerinin değerlendirilmesi. Ankara Üniversitesi Tıp Fakültesi Mecmuası 2002; 55(2): 123-8.
• Lin E, Calvono SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 2000; 127(2):117-26.
• Dinarello CA. IL-1: discoveries, controversies and future directions. Eur J Immunol 2010; 40(3): 599-606.
• Dinarello CA. Interleukin-1 beta and the autoinflammatory diseases. N Engl J Med 2009; 360(23): 2467-70.
• Bilgen SA, Kilic L, Akdogan A, et al. Effects of anti-tumor necrosis factor agents for Familial Mediterranean Fever patients with Chronic Arthritis and/or Sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol 2011; 17(7): 358-65.
• Saatci U, Bakkaloglu A, Ozen S, Besbas N. Familial Mediterranean fever and amyloidosis in children. Acta Paediatr 1993; 82(8): 705-6.
• Majeed HA, Rawashdeh M, El-Shanti H, Oubain H, Khuri-Bulos N, Shahin HM. Familial Mediterranean fever in children: the expanded clinical profile. QJM 1999; 92(6): 309-18.
• Guza G, Kanbay M, Ozturk MA. Current perspectives on familial Mediterranean fever. Curr Opin Infect Dis 2009; 22(3): 309–15.
• Gang N, Drenth JP, Langevitz P, et al. Activation of the cytokine network in familial Mediterranean Fever. J Rheumatol 1999; 26(4): 890–7.
• Kivity S, Danilesko I, Ben-Zvi I, et al. Serum amyloid A levels in kidney-transplanted patients with familial Mediterranean fever-amyloidosis. Isr Med Assoc J 2011; 13(4): 202-5.
• Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77(4): 268–30.
• Ergüven M, Emeksiz C, Deveci M, Özlü SG. Relation between microalbuminuria and gene mutations in familial Mediterranean fever. Turk J Pediatr 2008; 50(4): 326-5.
• Koşan C. Ailevi Akdeniz Ateşine tanısal yaklaşım. AÜTD 2003; 35: 1-6.
• Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of Familial Mediterranean Fever. Arthritis Rheum 1997; 40(10): 1879-85.
• Guzel S, Andican G, Seven A, et al. Acute phase response and oxidative stress status in Familial Mediterranean Fever (FMF). Mod Rheumatol 2012; 22(3): 431-7.
• Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994; 73(3): 133-44.
• McDermott EM, Smillie DM, Powell RJ. Clinical spectrum of familial Hibernian fever: A 14-year follow- up study of the index case and extended family. Mayo Clin Proc 1997; 72(9): 806-12.
• Padeh S, Brezniak N, Zemer D, et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: Clinical characteristics and outcome. J Pediatr 1999; 135(1): 98-4.
• Atagündüz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behcet's disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003; 21(4 Suppl 30):S35-7.
• Tekin M, Yalcinkaya F, Tumer N, Akar N, Misirlioglu M, Cakar N. Clinical, laboratory and molecular characteristics of children with familial Mediterranean fever-associated vasculitis. Acta Paediatr 2000; 89(2): 177-6.
• Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 1991; 34(8): 973-7.
• Lidar M, Kedem R, Langevitz P, Pras M, Livneh A. Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J Rheumatol. 2003; 30(12): 2620-3.
• Zemer D, Pras M, Sohar E, Modan B, Cabili S, Gafni J. Colchicine in the prevention and treatment of amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314(16): 1001-5.
• Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 1974; 291(18): 932-4.
• Rabinovitch O, Zemer D, Kukia E, Sohar E, Mashiach S. Colchicine treatment at conception and pregnancy: two hundred thirty-one pregnancies in patients with Familial Mediterranean Fever. Am J Reprod Immunol 1992; 28(3-4): 245-6.
• Ehrenfeld M, Brzezinski A, Levy M, Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol 1987; 94(12): 1186-6.
• Tunca M, Tankurt E, Akbaylar Akpinar H, Akar S, Hizli N, Gönen O. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol. 1997;36(9):1005-8.
• Tunca M, Akar S, Soytürk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol. 2004; 22(4 Suppl 34): 37-40.
• Seyahi E, Ozdogan H, Celik S, et al. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006; 24 (5 suppl 42): 99-5.
• Ozgocmen S, Ozçakar L, Ardicoglu O, et al. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 2006; 25(1): 83-7.
• Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008; 167(6): 695-6.